An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Clinical trial NCT07720284 · RECRUITING

Trial details

NCT number

NCT07720284

Sponsor

AstraZeneca

Status

RECRUITING

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2026-07-16

Primary completion

2030-09-11

Enrollment

915

View on ClinicalTrials.gov